2. Search Result
Search Result
Results for "

PbI 2

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

4

Natural
Products

1

Recombinant Proteins

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13719
    Oleandrin
    5 Publications Verification

    PbI-05204

    		 Na+/K+ ATPase Cancer
    Oleandrin (PBI-05204) inhibits the Na +, K +-ATPase activity with an IC50 of 620 nM.
    Oleandrin
  • HY-130086
    Bis-​PEG4-​NHS ester

    		ADC Linker Cancer
    Bis-PEG4-NHS ester is a crosslinking reagent and amine-reactive modulator [2].Bis-PEG4-NHS ester reacts with primary amine groups on liposome surfaces via amide bond formation to covalently attach dibenzylcyclooctyne groups, with a hydrophilic PEG4 spacer reducing steric hindrance for subsequent click chemistry .Bis-PEG4-NHS ester enables site-specific antibody coupling to liposome surfaces via copper-free strain-promoted alkyne-azide cycloaddition click chemistry without disrupting liposome structure in minimal organic solvent volumes .Bis-PEG4-NHS ester undergoes hydrolysis during annealing to form -COOH groups that interact with PbI and FAI to enhance perovskite structural integrity, passivate defects, and modulate nucleation kinetics to regulate crystal growth [2].Bis-PEG4-NHS ester enhances device efficiency and long-term stability when used as an antisolvent additive for p-i-n perovskite solar cells [2].
    Bis-​PEG4-​NHS ester
  • HY-100775
    Fezagepras sodium
    1 Publications Verification

    Setogepram sodium; PbI-4050 sodium

    		 Free Fatty Acid Receptor GPR84 Metabolic Disease Inflammation/Immunology
    Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras sodium decreases renal, liver and pancreatic fibrosis [2]. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions [2].
    Fezagepras sodium
  • HY-100775A
    Fezagepras
    1 Publications Verification

    Setogepram; PbI-4050

    		 Free Fatty Acid Receptor GPR84 Metabolic Disease Inflammation/Immunology
    Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis [2]. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions [2].
    Fezagepras
  • HY-153228
    Pomotrelvir
    1 Publications Verification

    PbI-0451

    		 SARS-CoV Infection
    Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (M pro), with an IC50 of 24 nM for wild-type SARS-CoV-2 M pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants [2].
    Pomotrelvir
  • HY-145587
    Paltimatrectinib

    PbI-200; PPI-5278

    		 Tyrosinase Trk Receptor Inflammation/Immunology Cancer
    Paltimatrectinib (compound I-147) is a potent tyrosine kinase inhibitor with an IC50 of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases .
    Paltimatrectinib
  • HY-W016414
    Triethyl phosphate

    		Environmental Pollutants Endogenous Metabolite Cardiovascular Disease
    Triethyl phosphate is a versatile phosphate ester compound. Triethyl phosphate induces rapid and short-acting anesthesia, and exhibits hypotensive, smooth muscle relaxant, and cardiac inhibitory effects. Triethyl phosphate also modulates cholinergic toxicity; its anesthetic effect shows sex- and age-dependency in rodents, and it interacts with SKF 525-A (HY-B1311) to alter the duration of anesthesia [2].
    Triethyl phosphate
  • HY-150723
    PBI-6DNJ

    		Glycosidase Metabolic Disease
    PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research .
    PBI-6DNJ
  • HY-N11060
    (Rac)-Dehydrovomifoliol

    PbI 344

    		 Others Others
    (Rac)-Dehydrovomifoliol (PBI 344) is a bisnorsesquiterpene compound that can be found in Euphorbia peplus .
    (Rac)-Dehydrovomifoliol
  • HY-123568
    PBI-1393

    BCH-1393

    		 TNF Receptor Cancer
    PBI-1393 (BCH-1393) is an anticancer agent that enhances Th1 type cytokine production and primary T cell activation .
    PBI-1393
  • HY-13719R
    Oleandrin (Standard)

    PbI-05204 (Standard)

    		 Reference Standards Na+/K+ ATPase Cancer
    Oleandrin (Standard) is the analytical standard of Oleandrin. This product is intended for research and analytical applications. Oleandrin (PBI-05204) inhibits the Na+, K+-ATPase activity with an IC50 of 620 nM.
    Oleandrin (Standard)
  • HY-100775R
    Fezagepras sodium (Standard)

    Setogepram sodium (Standard); PbI-4050 sodium (Standard)

    		 Reference Standards Free Fatty Acid Receptor GPR84 Metabolic Disease Inflammation/Immunology
    Fezagepras (sodium) (Standard) is the analytical standard of Fezagepras (sodium). This product is intended for research and analytical applications. Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras sodium decreases renal, liver and pancreatic fibrosis [2]. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions [2].
    Fezagepras sodium (Standard)
  • HY-100775AR
    Fezagepras (Standard)

    Setogepram (Standard); PbI-4050 (Standard)

    		 Reference Standards Free Fatty Acid Receptor GPR84 Metabolic Disease Inflammation/Immunology
    Fezagepras (Standard) is the analytical standard of Fezagepras. This product is intended for research and analytical applications. Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis [2]. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions [2].
    Fezagepras (Standard)
  • HY-N11060A
    (±)-Dehydrovomifolidol

    (±)-PbI 344

    		 Others Cancer
    (±)-Dehydrovomifoliol ((±)-PBI 344) is a norisoprenoid found in the rhizomes of Sinomenium acutum. (±)-Dehydrovomifoliolshows no significant cytotoxic activity against cancer cells .
    (±)-Dehydrovomifolidol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: